Vertex Pharmaceuticals Incorporated (VRTX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 127.47B USD. 52-week range 402.58 to 560.25 USD. Trailing P/E 29.3. Data as of 2026-10-09.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for ...